NEW YORK (GenomeWeb) – Serametrix, a San Diego-based company specializing in immune monitoring assays, has received CLIA certification for its laboratory in Carlsbad, California, the firm said recently.

The certification enables the company to offer its myeloid-derived suppressor cell assay for cancer patients. The flow cytometry-based assay was developed at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center and was licensed by Serametrix in 2013.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Human Longevity alleges that Craig Venter stole trade secrets in a lawsuit filed against the J. Craig Venter Institute.

A new paper critiques the analysis and conclusions of the Atacama mummy genome sequencing study.

In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.

An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

Aug
09
Sponsored by
Agena Bioscience

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.